Added 10 hours ago Drug news
Updated data from registration enabling NAVIGATOR trial of avapritinib for patients with PDGFRalpha, D842V-driven GIST and in second-, third- and fourth-line for other GIST patients. Blueprint Medicines
Blueprint Medicines Corporation announced updated data for the registration-enabling NAVIGATOR clinical trial of avapritinib, a potent and highly selective KIT...
Added 25 days ago Drug news
Phase III TAGS trial of Lonsurf in gastric cancer published in The Lancet Oncology.- Taiho Oncology.
Taiho Oncology announced the clinical data from the pivotal Phase III (TAGS) trial evaluating Lonsurf (trifluridine/tipiracil, TAS-102) versus placebo and...
Added 27 days ago Drug news
CHMP recommends approval of Ogivri biosimilar for breast cancer and gastric cancer.- Mylan + Biocon.
Mylan and Biocon announced that the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has issued a...
An epgonline.org Learning Zone (LZ) is an area of the site dedicated to providing detailed self-directed medical education about a disease, condition or procedure.
See information on best practice in solid organ transplantation, and expert discussions on related hot topics.
Experts discuss the use of non-vitamin K oral anticoagulants in the treatment and prevention of stroke, deep vein thrombosis and pulmonary embolism in atrial fibrillation patients.
View disease awareness information, treatment options and European Cystic Fibrosis Society best practice guidelines.
The Inflammatory Bowel Disease (IBD) Knowledge Centre contains key information relating to the epidemiology and pathophysiology of Crohn’s disease and ulcerative colitis, highlighting prevalence, impact and unmet needs and the underlying inflammatory processes that drive IBD, considering some of the key inflammatory pathways.
The CDK 4/6 Inhibitors in Metastatic Breast Cancer Learning Zone provides insights and information for metastatic breast cancer (mBC) and CDK 4/6 signalling. This includes the burden and pathophysiology of the disease, the role of CDK 4/6 in cell proliferation and an overview of the CDK 4/6 inhibitors that have been approved for the management of mBC.
The ESMO Clinical Practice Guidelines (CPG) are intended to provide the user with a set of recommendations for the best...
Added 5 years ago
Neuroendocrine gastro-entero-pancreatic tumors: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Neuroendocrine gastroenteropancreatic tumors (GEP-NETs) constitute a heterogeneous group of tumors with their origin in neuroendocrine cells of the embryological gut. This guideline focuses on diagnosis and pathology/molecular biology...
Added 6 years ago
BSG guidelines for the management of gastroenteropancreatic neuroendocrine (including carcinoid) tumours (NETs)
Over the past few years, there have been advances in the management of neuroendocrine tumours, which have included clearer characterisation, more specific and therapeutically relevant diagnosis, and improved treatments.
Added 6 years ago
Trastuzumab-induced cardiotoxicity and its risk factors in real-world setting of breast cancer patients.
The aim of this retrospective study was to determine the frequency and timing of trastuzumab cardiotoxicity and its risk factors in real-world setting.
Added 5 months ago
Ramucirumab for the treatment of patients with gastric or gastroesophageal junction cancer in community oncology practices.
Background: Limited real-world research has investigated ramucirumab for the treatment of patients with gastric or gastroesophageal junction (GEJ) cancer.
Added 6 months ago
Ramucirumab as Second-Line Therapy in Metastatic Gastric Cancer: Real-World Data from the RAMoss Study.
Objective: The RAMoss study aimed to evaluate the safety and efficacy profile of ramucirumab in the "real-life setting".
Added 6 months ago
This study is aimed to evaluate the safety of applying enhanced recovery after surgery for gastric cancer.
Added 1 year ago
The purpose of this trial is to compare the effects of TAS-102 and best supportive care (BSC) with Placebo (an inactive drug) and best supportive care on metastatic gastric cancer.
Added 3 months ago
A Study of Ramucirumab (LY3009806) in Combination With Capecitabine and Cisplatin in Participants With Stomach Cancer (RAINFALL)
The main purpose of this study is to evaluate the effectiveness of ramucirumab, which is a targeted antibody, in combination with capecitabine and cisplatin compared to capecitabine and cisplatin alone in participants with stomach cancer.
Added 11 months ago
Fiona worked in the fitness and wellness industry in the US for 13 years, supporting behaviour change in a variety of settings. Fiona’s research interests lie broadly within health and wellbeing. She is particularly interested in qualitative methodologies in the areas of body image ... Read more
Ahead of World Cancer Day on Saturday (February 4), Fiona Holland, Psychology Lecturer, discusses what to say and what not to say to someone with cancer.